Phathom Pharmaceuticals, Inc. (PHAT)Healthcare | Biotechnology | Florham Park, United States | NasdaqGS
12.88 USD
-0.59
(-4.380%) ⇩
(April 21, 2026, 4 p.m.
EDT)
After hours: 12.95 +0.07 (0.535%) ⇧ (April 21, 2026, 7:16 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:04 a.m. EDT
This is a polarized play: fundamentally promising due to 94% revenue growth and a 'Strong Buy' analyst consensus, but technically and sentimentally weak. The near-term IV skew in puts indicates the market pricing in pain ahead of earnings or phase 3 results, making it a risky entry for momentum traders, despite the attractive forward P/E of 8.5 |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.170950 |
| AutoETS | 0.190607 |
| AutoARIMA | 0.192175 |
| AutoTheta | 0.195288 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 2.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.312 |
| Excess Kurtosis | -0.95 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 2.401 |
| Market Cap | 1,023,059,968 |
| Forward P/E | 8.34 |
| Beta | 0.61 |
| Profit Margins | -126.35% |
| Website | https://www.phathompharma.com |
As of April 19, 2026, 12:04 a.m. EDT: Options data reveals high implied volatility (IV) specifically in short-term puts (April 17 ATM IV 9.15), signaling strong defensive hedging activity rather than bullish aggression. In-the-money (ITM) call volume is low relative to put volume in near-term expirations, while long-dated calls (2028) show heavy concentration at low strikes (7.50-10.00), indicating capital preservation strategies. The disparity between the high ATM IV of near-term puts (9.15) and low-term puts (1.07 vs 1.07) suggests the market expects continued volatility and potential downside, with speculators positioning for a range rather than a directional break above current levels.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2039802 |
| Address1 | 100 Campus Drive |
| Address2 | Suite 102 |
| All Time High | 64.54 |
| All Time Low | 2.21 |
| Ask | 12.9 |
| Ask Size | 9 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 1,047,730 |
| Average Daily Volume3 Month | 1,034,357 |
| Average Volume | 1,034,357 |
| Average Volume10Days | 1,047,730 |
| Beta | 0.61 |
| Bid | 12.69 |
| Bid Size | 9 |
| Board Risk | 6 |
| Book Value | -6.135 |
| City | Florham Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.88 |
| Current Ratio | 1.734 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.51 |
| Day Low | 12.515 |
| Display Name | Phathom Pharmaceuticals |
| Earnings Call Timestamp End | 1,777,550,400 |
| Earnings Call Timestamp Start | 1,777,550,400 |
| Earnings Timestamp | 1,777,552,200 |
| Earnings Timestamp End | 1,777,552,200 |
| Earnings Timestamp Start | 1,777,552,200 |
| Ebitda | -159,352,992 |
| Ebitda Margins | -0.91002 |
| Enterprise To Ebitda | -9.251 |
| Enterprise To Revenue | 8.418 |
| Enterprise Value | 1,474,126,208 |
| Eps Current Year | 0.01275 |
| Eps Forward | 1.5442 |
| Eps Trailing Twelve Months | -2.9 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.6325 |
| Fifty Day Average Change | 1.2475004 |
| Fifty Day Average Change Percent | 0.10724268 |
| Fifty Two Week Change Percent | 220.39803 |
| Fifty Two Week High | 18.31 |
| Fifty Two Week High Change | -5.4299994 |
| Fifty Two Week High Change Percent | -0.29655924 |
| Fifty Two Week Low | 2.21 |
| Fifty Two Week Low Change | 10.67 |
| Fifty Two Week Low Change Percent | 4.8280544 |
| Fifty Two Week Range | 2.21 - 18.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,572,010,200,000 |
| Float Shares | 59,388,999 |
| Forward Eps | 1.5442 |
| Forward P E | 8.340889 |
| Free Cashflow | -107,858,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 371 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.87094 |
| Gross Profits | 152,511,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04581 |
| Held Percent Institutions | 0.83092004 |
| Implied Shares Outstanding | 79,430,117 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. |
| Long Name | Phathom Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,023,059,968 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_613615658 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -221,247,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,069,923,675 |
| Number Of Analyst Opinions | 10 |
| Open | 13.51 |
| Operating Cashflow | -166,775,008 |
| Operating Margins | -0.10295 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 877 742 8466 |
| Post Market Change | 0.06890011 |
| Post Market Change Percent | 0.53493875 |
| Post Market Price | 12.9489 |
| Post Market Time | 1,776,813,369 |
| Previous Close | 13.47 |
| Price Eps Current Year | 1,010.1961 |
| Price Hint | 2 |
| Price To Book | -2.0994294 |
| Price To Sales Trailing12 Months | 5.842385 |
| Profit Margins | -1.26347 |
| Quick Ratio | 1.576 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.36364 |
| Region | US |
| Regular Market Change | -0.59 |
| Regular Market Change Percent | -4.38011 |
| Regular Market Day High | 13.51 |
| Regular Market Day Low | 12.515 |
| Regular Market Day Range | 12.515 - 13.51 |
| Regular Market Open | 13.51 |
| Regular Market Previous Close | 13.47 |
| Regular Market Price | 12.88 |
| Regular Market Time | 1,776,801,600 |
| Regular Market Volume | 1,423,681 |
| Return On Assets | -0.31371 |
| Revenue Growth | 0.941 |
| Revenue Per Share | 2.401 |
| Sand P52 Week Change | 0.3140242 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 79,430,117 |
| Shares Percent Shares Out | 0.1339 |
| Shares Short | 10,637,936 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 11,169,289 |
| Short Name | Phathom Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.14109999 |
| Short Ratio | 9.36 |
| Source Interval | 15 |
| State | NJ |
| Symbol | PHAT |
| Target High Price | 29.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 23.7 |
| Target Median Price | 25.5 |
| Total Cash | 129,972,000 |
| Total Cash Per Share | 1.649 |
| Total Debt | 589,171,008 |
| Total Revenue | 175,110,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.45475 |
| Two Hundred Day Average Change | 0.42525005 |
| Two Hundred Day Average Change Percent | 0.034143604 |
| Type Disp | Equity |
| Volume | 1,423,681 |
| Website | https://www.phathompharma.com |
| Zip | 7,932 |